Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö > ¸ÂÃãÇüÀÇ·á > ¸ÂÃãÇü ÀÇ·á(Personalized Medicine) : ÇâÈÄÀÇ Ä¡·á¹ý¿¡ ´ëÇ×Çϱâ À§ÇÑ Àΰ£À¯ÀüüÇÐ(Human Genomics), ÇÁ·ÎÅ׿À¹Í½º(Proteomics)ÀÇ ÁøÈ­
Ä«Å×°í¸®
¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö (1590)
°Ô³ð â¾à (202)
¸ÂÃãÇüÀÇ·á (51)
¹ÙÀÌ¿À¸¶Ä¿ (154)
¹ÙÀÌ¿À¸ÅÆ®¸®¾ó (54)
¹ÙÀÌ¿ÀÀåºñ (357)
ºÐÀÚÇ¥ÀûÄ¡·á(MTT) (131)
À¯ÀüÀÚ Ä¡·á/RNAi (101)
Àç»ýÀÇÇÐ (124)
Ç×ü/¸é¿ª (191)
½ÃÀ庸°í¼­

¸ÂÃãÇü ÀÇ·á(Personalized Medicine) : ÇâÈÄÀÇ Ä¡·á¹ý¿¡ ´ëÇ×Çϱâ À§ÇÑ Àΰ£À¯ÀüüÇÐ(Human Genomics), ÇÁ·ÎÅ׿À¹Í½º(Proteomics)ÀÇ ÁøÈ­

Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics

¸®¼­Ä¡»ç GBI Research
¹ßÇàÀÏ 2010³â 12¿ù »óǰÄÚµå 139758
ÆäÀÌÁö Á¤º¸ Pages: 124
°¡°Ý
US $ 3,500 £Ü 4,170,200 PDF by E-mail (Single user license)
US $ 7,000 £Ü 8,340,500 PDF by E-mail (Site license)
US $ 10,500 £Ü 12,510,700 PDF by E-mail (Global license)


GBI Research ¿¡¼­ 2010³â 12¿ù ¿¡ ¹ßÇàÇÑ ¡¸¸ÂÃãÇü ÀÇ·á(Personalized Medicine) : ÇâÈÄÀÇ Ä¡·á¹ý¿¡ ´ëÇ×Çϱâ À§ÇÑ Àΰ£À¯ÀüüÇÐ(Human Genomics), ÇÁ·ÎÅ׿À¹Í½º(Proteomics)ÀÇ ÁøÈ­¡¹ º¸°í¼­´Â Pages: 124·Î ±¸¼ºµÇ¾î, US $3,500 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

¸ÂÃãÇü ÀÇ·á(Personalized Medicine) ½ÃÀå¿¡ °ü·ÃµÈ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× ÀúÇØ¿äÀÎ, ÇöÀçÀÇ ¾àÁ¦ ÇÁ·ÎÆÄÀÏ, ÆÄÀÌÇÁ¶óÀÎ Á¦Ç° ÇÁ·ÎÆÄÀÏ ¹× ¿¬±¸ µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ ¹× °æÀï µ¿Çâ µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

    Á¦1Àå ¸ñÂ÷
    Á¦2Àå ¸ÂÃãÇü ÀÇ·á(Personalized Medicine) ½ÃÀå : ½ÃÀå °³¿ä
    Á¦3Àå ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ¹× ÀúÇØ¿äÀÎ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
      • ÀÇ·áºñÀÇ Áõ´ë
      • ±âÁ¸ÀÇ Drug Discovery¸¦ ´É°¡ÇÏ´Â ÀÌÁ¡
      • ȯÀÚÀÇ ÀûÇÕ¼º
      • ÁúȯÀÇ Á¶±â¹ß°ß
      • º¸´Ù ÁÁÀº ¹ý±ÔÁ¦ ±âÁذú ºñÁØ ¼ö¼øÀÌ ¸ÂÃãÇü ÀÇ·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁø
    • ½ÃÀå ¼ºÀå ÀúÇØ¿äÀÎ
      • ÁöºÒÀÚ »óȯ ¹®Á¦
      • À±¸®Àû ¹®Á¦
      • ÀÇ·á Á¤º¸ ±â¼ú
      • ÀνÄÀÇ °ÝÂ÷ : ÀÇ»çÀÇ ±³À° ºÎÁ·°ú ½Å±â¼ú¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·
      • ¹ø°Å·Ó°í ±ä °³¹ß ¼ö¼øÀÌ ÀǾàǰ ºÎ¹®ÀÇ ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸ ÀÇ¿åÀ» ÀúÁö
    Á¦4Àå ¸ÂÃãÇü Ä¡·áÁ¦¿Í Áø´Ü¾à
    • Ä¡·áÁ¦ : ¾àÁ¦ °³¿ä
    • µ¿¹ÝÁø´Ü
      • ¸ÂÃãÇü ÀÇ·á¿¡¼­ ä¿ëµÇ´Â µ¿¹ÝÁø´Ü
    • ¹ÙÀÌ¿À¸¶Ä¿
      • ¾Ï ¿¬±¸¿¡¼­ÀÇ ¹ÙÀÌ¿À¸¶Ä¿
      • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
      • ÀûÀÀº° ¼¼ºÐÈ­
    Á¦5Àå ÆÄÀÌÇÁ¶óÀÎ Á¦Ç° ÇÁ·ÎÆÄÀÏ
    • PF-4948568
    • PF-02341066 + Erlotinib
    • PF-299804
    • CEP-701
    • TBR-652
    • Brivanib
    • Ipilimumab
    • BiovaxID (Accentia Biopharmaceuticals, Inc
    Á¦6Àå ¸ÂÃãÇü ÀÇ·áÀÇ ¿¬±¸ µ¿Çâ
    Á¦7Àå °æÀï ȯ°æ
    • °æÀï ÇÁ·ÎÆÄÀϸµ
    • Clarient, Inc
    • Qiagen N.V.
    • Laboratory Corporation of America Holdings
    • bioMerieux S.A
    • Pfizer
    • Eli Lily and Company
    • Novartis
    • F. Hoffman La Roche
    • Bristol-Myers Squibb
    • Merck KGaA
    • Dako Denmark A/S
    Á¦8Àå °á·Ð
    Á¦9Àå ºÎ·Ï
    µµÇ¥
LSH
Back to Top